B
Biosplice Therapeutics
Medical research and development for tissue-level regeneration
At a glance
- Founded
- 2008
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tier
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Biosplice Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- EVEsas Ventures
Series A3 investors entered at this stage
- SGStarling group
- PVPolar Light Ventures
- VPVickers Venture Partners
Series B and later6 investors entered at this stage
- CCChristian Cadeo
- SGSymbiosis Group
- EMEventide Asset Management
- COCem Ortabaş
- AFaMoon Fund
- VMVerition Fund Management
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
70 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biosplice Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biosplice Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.